HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer Center
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2025.12.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von C Natasha Kwendakwema und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Cen…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Hepatitis C, Hepatitis B, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: University of Washington, University of Washington Fred Hutch Center for AIDS Research.
Abstract (Originalsprache)
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype non-Hodgkin lymphoma. HIV, hepatitis B (HBV), and hepatitis C (HCV) infections are DLBCL risk factors. DLBCL remains a leading cause of cancer-related morbidity and mortality in those with HIV. DLBCL treatments can also increase the HBV reactivation risk and acute liver injury in HCV. We assessed HBV, HCV, and HIV screening rates in DLBCL patients receiving systemic therapy in a comprehensive cancer system. MATERIALS AND METHODS: We analyzed newly diagnosed DLBCL patients receiving anti-CD20 therapies between January 2018 and December 2023. Patients were considered screened if they had viral testing or a prior diagnosis within 12 months before to 3 months after starting treatment. We used chi-squared and Fisher's exact tests to examine associations between patients who were and were not screened HBV, HCV, and HIV. We used univariate and multivariate logistic regression to identify the factors associated with screening. RESULTS: A total of 535 patients with DLBCL were treated (median age 64, 42% female, 82% white). Among these patients, 410 (77%) had HBV testing or a known infection, 275 (51.4%) had HIV testing or a known infection, and 307 (53%) had HCV testing or a known infection. Younger people were more likely to be tested for HIV and HCV. There was no association between age and HBV testing. CONCLUSION: Pre-treatment HIV, HBV, and HCV screening rates in newly diagnosed DLBCL patients remains suboptimal. Interventions to increase viral testing in this population could help reduce treatment-related morbidity and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA. Electronic address: ckwendak@fredhutch.org.
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA.
- Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
- Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA; Department of Medicine, Division of Allergy and Infe…
Förderung
- University of Washington
- University of Washington Fred Hutch Center for AIDS Research
Zitieren
APA
Kwendakwema, C. N., Lan, K. F., Kim, H. N., Gopal, A. K., & Menon, M. P. (2026). HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer Center. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.010
Vancouver
Kwendakwema CN, Lan KF, Kim HN, Gopal AK, Menon MP. HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer Center. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.12.010
BibTeX
@article{Kwendakwema2026,
author = {Kwendakwema, C Natasha and Lan, Kristine F and Kim, H Nina and Gopal, Ajay K and Menon, Manoj P},
title = {HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer Center},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2025.12.010}
}
EUVIMED